跳到主要內容區
 
:::

翁芸芳(Ueng, Yune-Fang)

翁芸芳個人生活照姓名:翁芸芳(Ueng, Yune-Fang
職稱:研究員兼中醫藥基礎研究組組長
電話:2820-1999 轉6351、6361

E-mailueng@nricm.edu.tw

學歷:

國立台灣大學 醫學院 生物化學研究所 博士
高雄醫學院 藥學系 學士

主要經歷:

臺北醫學大學  兼任教授
國立陽明交通大學 藥物科學院、醫學院 兼任副教授
美國范德堡大學 醫學院 生化所暨分子毒理中心 博士後研究員
國立台灣大學 醫學院 毒理學研究所 博士後副研究員


其他經歷:

台灣毒物學會幹事 
台灣藥理學會藥理簡訊編輯委員 
台灣毒物學會會員 
台灣藥理學會會員
期刊編輯/諮詢編輯委員: J. Food Drug Anal.、Drug Metab. Pharmacokinet.

學術榮譽事項:
中華民國斐陶斐榮譽學會 
毒藥物防治學術獎座

專長:
藥物代謝,藥學 ,生化毒理學

研究簡介:
      藥物代謝酶在外來物包括天然物、藥物、環境污染物之生物活性及解毒作用中扮演重要角色。
研究主題在
(一)、探討天然物與藥物代謝酶之相互影響以評估產生藥物交互作用之可能性;
(二)、確認天然物之代謝產物並了解參與其代謝之人類藥物代謝酶。

期刊論文: 所內研究人員(用Email)點選編輯點此編輯

      NCBI PubMed :  Yune-Fang Ueng (Please click!!)

Selected Publications:

  1. Pan, S. Y., Chi, K. H., Wang, Y.-C., Wei, W.-C., and Ueng, Y.-F.* (2022) Sub-toxic events induced by truck speed-facilitated PM2.5 in A549 human lung cells: counteraction by epigallocatechin-3-gallate. Sci. Report., in press.

  2. Wang, H.-J., Tan, E. C.-H., Chiang, T.-Y., Chen, W.-C., Shen, C.-C., and Ueng, Y.-F.* (2022) Effect of repeated Shengmai-San administration on nifedipine pharmacokinetics and the risk/benefit under co-treatment. J. Food Drug Anal. 30, 111-127.

  3. Chiang, T.-Y., Wang, H.-J., Wang, Y.-C., Tan, E. C.-H., Lee, I-J., Yun, C.-H., and Ueng, Y.-F.* (2021) Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats. J. Ethnopharmacol., 271, 113914.

  4. Huang, C.-T., Tseng, L.-M., Chen, J.-L., Chu, P.-Y., Lee, C.-H., Huang, C.-T., Wang, W.-L., Lau, K.-Y., Tseng, M.-F., Chang, Y.-Y., Chiang, T.-Y., Ueng, Y.-F., Lee, H.-C., Dai, M.-S., and Liu, C.-Y.* (2020) Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression. EBioMedicine 54, 102717.

  5. Ueng, Y.-F.a, Wang, H.-J.a, Wu, S. C., and Ng, Y.-Y.* (2019) A thrice weekly ertapenem is practical for hemodialysis patients. Antimicrobial Agent. Chemother., 63, e01427-19, 1-7.

  6. Chao, T.-C., Pan, W.-C., Tsai, Y.-F., Chou, Y.-C., Liu, Y.-R., Wang, S.-F., Chen, Y.-J., Souček, P., and Ueng, Y.-F.*, Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol. Toxicol. Appl. Pharmacol. 378, 114619, 2019

  7. Lo, S.-N., Wang, C.-W., Chen, Y.-S., Huang, C.-C., Wu, T.-S., Li, L.-A., Lee, I-J., and Ueng, Y.-F.* (2017), Berberine activates aryl hydrocarbon receptor but suppress CYP1A1 induction through miR-21-3p stimulation in MCF-7 breast cancer cells. Molecules, 22, 1847, doi: 10.3390/molecules22111847.

  8. Chen, P.-C., Tsai, W.-J., Ueng, Y.-F., Tzeng, T.-T., Chen, H.-L., Zhu, P.-R., Huang, C.-H., Shiao, Y.-J., Li, W.-T.*(2017) Neuroprotective and anti-neuroinflammatory effects of hydroxyl-functionalized stilbenes and 2-arylbenzo[b]furans. J. Med. Chem., 60, 4062–4073.

  9. Ueng, Y.-F.*, Lu, C.-K., Yang, S.-H., Wang, H.-J., and Huang C.-C. (2017) Potentiation of the anticoagulation effect of warfarin by the herbal remedy Shu-Jing-Hwo-Shiee-Tang in rats: the dosing regimen and pharmacokinetic interaction. Drug Metab. Pharmacokinet., 32, 85-91.

  10. Chang, Y.-P., Huang, C.-C., Shen, C.-C., Tsai, K.-C., and Ueng, Y.-F.* (2015) Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites. Drug Metab. Pharmacokinet., 30, 374-383.

  11. Lo, S.-N., Shen, C.-C., Chang, C.-Y., Tsai, K.-C., Huang, C.-C., Wu, T.-S., and Ueng, Y.-F.* (2015) The effect of oxidation on berberine-mediated CYP1 inhibition: oxidation behavior and metabolite-mediated inhibition. Drug Metab. Dispos., 43, 1100-1107.

  12. Lee, K.-H.a, Ueng, Y.-F.aWu, C.-W., Chou, Y.-C., Ng, Y.-Y.*, Yang, W.-C. (2014) The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in hemodialysis patients – case reports and literature reviews. J. Clin. Pharm. Therapeut. doi: 10.1111/jcpt.12239.

  13. Lo, S.-N., Chang, Y.-P., Tsai, K.-C., Chang, C.-Y., Wu, T.-S.**, and Ueng, Y.-F.* (2013) Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. Toxicol. Appl. Pharmacol., 272, 671-680.

  14. Wang, S.-F., Chou, Y.-C., Mazumder, N., Kao, F.-J., Nagy L. D., Guengerich, F. P., Huang, C., Lee, H.-C., Lai, P.-S., and Ueng, Y.-F.* (2013) 7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells. Biochem. Pharmacol., 86,548-560.

  15. Ueng, Y.-F.*, Chen, C.-C., Yamazaki, H., Kiyotani, K., Chang, Y.-P., Lo, W.-S., Li, D.-T., and Tsai, P.-L. (2013) Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. Drug Metab. Pharmacokinet. 28, 229-238.

  16. Lo W.-S., Lim Y.-P., Chen, C.-C., Hsu, C.-C., Souček, P., Yun, C.-H., Xie, W., and Ueng Y.-F.* (2012) A dual function of the furanocoumarin chalepensin in inhibiting Cyp2a and inducing Cyp2b in mice: the protein stabilization and receptor-mediated activation. Arch. Toxicol., 86, 1927-1938.

  17. Souček, P., Kondrová, E., Heřmánek, J., Stopka, P., Boumendjel, A., Ueng, Y.-F., and Gut, I. (2011). New model system for testing effects of flavonoids on doxorubicin-related formation of hydroxyl radicals. Anti-cancer Drugs, 22(2), 176-184. doi:10.1097/CAD.0b013e328341a17b

  18. Ueng, Y.-F., Chen, C.-C., Chung, Y.-T., Liu, T.-Y., Chang, Y.-P., Lo, W.-S., Li, D.-T. (2011). Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. British Journal of Pharmacology, 163(6), 1250-1262. doi:10.1111/j.1476-5381.2011.01341.x

  19. Ueng, Y.F* Tsai, C.C., Lo, W.S., Yun, C.H. (2010) Induction of hepatic cytochrome P450s by the herbal medicine, Sophora flavescens extract in rats: the impact on the elimination of theophylline. Drug Metab. Pharmacokinet.,25:560–567.

  20. Chou, Y.C., Lin, M.H., Chung, Y.T., Liu, T.Y., Wang, S.Y., Chau, G.Y., Chi, C.W., Lee,C.H., Souček, P.,Krausz, K., Gelboin, H.V., and Ueng, Y.F.* (2010) The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J. Pharm. Sci., 99, 1063-1077.

  21. Ueng, Y.F.*, Chen, C.C., and Tsai, C.C. (2009) Differential inductive profiles of  hepatic cytochrome P450s by the extracts of Sophora flavescens in male and female C57BL/6JNarl mice. J. Ethnopharmacol., 126,437-446.

  22. Pan, W.C., Chen, R.M., Shen, Y.C., Chen, C.C., and Ueng, Y.F.* (2009) Suppressive effect of tobacco smoke extracts on oral P-glycoprotein function and its impact in smoke-induced insult to oral epidermal cells. Toxicol. Lett., 185, 116-123.

  23. Wu G.J., Chen T.L., Ueng Y.F., and Chen R.M.* (2008) Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharidestimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol., 228, 105-113.

  24. Su C.R., Ueng Y.F., Dung N.X., Reddy V.B., and Wu T.S. (2007) Cytochrome P450 3A4 inhibitors and other constituents of Fibraurea tinctoria. J. Nat. Prod., 70, 1930-1933.

  25. Ueng Y.F.*, Jan W.C., Don M.J., Ho L.K., and Chen C.F. (2006) Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450s. Drug Metab. Dispos., 34, 821-827.

  26. Kuo Y.H., Lin Y.L., Don M.j., Chen R.M., and Ueng Y.F.*(2006) Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J. Pharm. Pharmacol., 58, 521-527

  27. Ueng Y.F.*, Yu H.J., Lee C.H., Peng C., Jan W.C., Ho L.K., Chen C.F., and Don M.J.* (2005) Identification of the microsomal oxidation metabolites of rutaecarpine, a main active alkaloid of the medicinal herb Evodia rutaecarpa. J. Chromatogr. A, 1076, 103-109

  28. Ueng Y.F.*, Chieh C.H., and Don M.J. (2005) Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Food Chem. Toxicol., 43, 707-712.

  29. Ueng, Y.-F.*, Hsieh, C.-H., Don, M.-J. and Ho, L.-K. (2004) Identification of the main cytochrome P450 involved in safrole 1’-hydroxylation. Chem. Res. Toxicol.,17, 1151-1156.

  30. Ueng, Y.-F.*, Jan, W.-C., Lin, L.-C., Chen, T.-L., Guengerich, F. P., and Chen, C.-F. (2002) The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes. Drug Metab. Dispos., 30, 349-353.

  31. Ueng, Y.-F.*, Shyu, C.-C., Liu, T.-Y., Oda, Y., Lin, Y.-L., Liao, J.-F., and Chen, C.-F. (2001) Protective effects of baicalein and wogonin against benzo(a)pyrene and aflatoxin B1-induced genotoxicities. Biochem. Pharmacol. 62, 1653-1660.

  32. Ueng, Y.-F., Shimada, T., Yamazaki, H., and Guengerich, F. P.* (1998) Aflatoxin B1 oxidation by human cytochrome P450s. J. Toxicol. Sci., 23, Suppl. II, 132-135.

  33. Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., and Guengerich, F. P.* (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36: 370-381.

  34. Ueng, Y.-F., Shimada, T., Yamazaki, H., and Guengerich, F. P.* (1995), Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8: 218-225.

瀏覽數: